

The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Hikma Pharmaceuticals USA Inc. is initiating a market withdrawal of thirteen (13) lots of Lorazepam Injection, USP and Ativan (Lorazepam Inj. USP) 2mg/mL and 4mg/mL, 1ml fill vials at the retail level. This market withdrawal is being conducted with the knowledge of the Food and Drug Administration.

This market withdrawal is being conducted as a precautionary measure. This is being executed out of abundance of caution as the product may exceed the total related compound specification prior to end of shelf-life. We have received no Adverse Events complaints for the subject lots to date.

NDC	Item Description	Lot	Exp. Date	First Ship Date	Last Ship Date
0641-6001-25	ATIVAN (LORAZEPAM INJ.) 2MG/ML VIAL X 25	D241002	Apr-26	6/10/2024	6/11/2024
0641-6001-25	ATIVAN (LORAZEPAM INJ.) 2MG/ML VIAL X 25	D241062	Apr-26	6/4/2024	6/11/2024
0641-6003-25	ATIVAN (LORAZEPAM INJ.) 4MG/ML VIAL X 25	G24103L	Jul-26	9/16/2024	4/7/2025
0641-6044-25	LORAZEPAM 2MG/ML VIAL X 25	C24099	Mar-26	5/24/2024	6/3/2024

0641-6044-25	LORAZEPAM 2MG/ML VIAL X 25	D24098	Apr-26	6/4/2024	6/13/2024
0641-6044-25	LORAZEPAM 2MG/ML VIAL X 25	D24104	Apr-26	6/13/2024	6/17/2024
0641-6044-25	LORAZEPAM 2MG/ML VIAL X 25	D24115	Apr-26	6/17/2024	6/25/2024
0641-6045-25	LORAZEPAM 4MG/ML VIAL X 25	G24103	Jul-26	9/16/2024	12/2/2024
0641-6048-25	LORAZEPAM NOVA+ 2MG/ML VIAL X 25	H24079Z	Aug-26	10/3/2024	11/18/2024
0641-6049-25	LORAZEPAM NOVA+ 4MG/ML VIAL X 25	G24103Y	Jul-26	9/16/2024	4/21/2025
72572-380-25	LORAZEPAM CIVICA 2MG/ML VIAL X 25	8240722	Feb-26	3/22/2024	3/22/2024
72572-380-25	LORAZEPAM CIVICA 2MG/ML VIAL X 25	C24097Z	Mar-26	5/22/2024	5/22/2024

72572-
380-25

LORAZEPAM CIVICA
2MG/ML VIAL X 25

D241022

Apr-26

5/29/2024

5/29/2024